GLAXOPharmaceuticals
GlaxoSmithKline Pharmaceuticals Ltd — Balance Sheet
₹2283.00
-3.43%
GlaxoSmithKline Pharmaceuticals Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Ordinary Shares Number | 16.94 Cr | 16.94 Cr | 16.94 Cr | 16.94 Cr | — |
| Share Issued | 16.94 Cr | 16.94 Cr | 16.94 Cr | 16.94 Cr | — |
| Total Debt | 9.95 Cr | 18.66 Cr | 15.54 Cr | 20.08 Cr | — |
| Tangible Book Value | 1.94K Cr | 1.75K Cr | 1.71K Cr | 2.63K Cr | — |
| Invested Capital | 1.95K Cr | 1.78K Cr | 1.74K Cr | 2.66K Cr | — |
| Working Capital | 1.50K Cr | 1.27K Cr | 1.17K Cr | 2.01K Cr | — |
| Net Tangible Assets | 1.94K Cr | 1.75K Cr | 1.71K Cr | 2.63K Cr | — |
| Capital Lease Obligations | 9.95 Cr | 18.66 Cr | 15.54 Cr | 20.08 Cr | — |
| Common Stock Equity | 1.95K Cr | 1.78K Cr | 1.74K Cr | 2.66K Cr | — |
| Total Capitalization | 1.95K Cr | 1.78K Cr | 1.74K Cr | 2.66K Cr | — |
| Total Equity Gross Minority Interest | 1.95K Cr | 1.78K Cr | 1.74K Cr | 2.66K Cr | — |
| Stockholders Equity | 1.95K Cr | 1.78K Cr | 1.74K Cr | 2.66K Cr | — |
| Other Equity Interest | -14.88 Cr | -9.01 Cr | -1.68 Cr | 2.49K Cr | — |
| Retained Earnings | 1.06K Cr | 876.44 Cr | 811.49 Cr | 1.73K Cr | — |
| Additional Paid In Capital | 2.62 Cr | 2.62 Cr | 2.62 Cr | 2.62 Cr | — |
| Capital Stock | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr | — |
| Common Stock | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr | — |
| Total Liabilities Net Minority Interest | 2.16K Cr | 1.78K Cr | 1.59K Cr | 1.97K Cr | — |
| Total Non Current Liabilities Net Minority Interest | 251.60 Cr | 254.03 Cr | 258.94 Cr | 271.89 Cr | — |
| Long Term Debt And Capital Lease Obligation | 2.49 Cr | 6.47 Cr | 3.46 Cr | 7.62 Cr | — |
| Long Term Capital Lease Obligation | 2.49 Cr | 6.47 Cr | 3.46 Cr | 7.62 Cr | — |
| Long Term Provisions | 249.11 Cr | 247.46 Cr | 254.80 Cr | 262.21 Cr | — |
| Current Liabilities | 1.91K Cr | 1.52K Cr | 1.33K Cr | 1.70K Cr | — |
| Other Current Liabilities | 0.07 Cr | 1.77 Cr | 0.06 Cr | 0.17 Cr | — |
| Current Debt And Capital Lease Obligation | 7.46 Cr | 12.20 Cr | 12.08 Cr | 12.45 Cr | — |
| Current Capital Lease Obligation | 7.46 Cr | 12.20 Cr | 12.08 Cr | 12.45 Cr | — |
| Current Provisions | 416.41 Cr | 393.52 Cr | 417.79 Cr | 319.16 Cr | — |
| Payables | 1.47K Cr | 1.11K Cr | 888.05 Cr | 1.36K Cr | — |
| Other Payable | 217.95 Cr | 166.02 Cr | 144.94 Cr | 467.18 Cr | — |
| Dividends Payable | 22.59 Cr | 18.60 Cr | 19.12 Cr | 18.28 Cr | — |
| Total Tax Payable | 524.52 Cr | 298.58 Cr | 296.20 Cr | 296.20 Cr | — |
| Accounts Payable | 708.25 Cr | 625.41 Cr | 427.79 Cr | 579.33 Cr | — |
| Total Assets | 4.11K Cr | 3.56K Cr | 3.33K Cr | 4.63K Cr | — |
| Total Non Current Assets | 698.18 Cr | 758.20 Cr | 832.32 Cr | 925.25 Cr | — |
| Other Non Current Assets | 0.43 Cr | 0.61 Cr | 1.08 Cr | 1.33 Cr | — |
| Defined Pension Benefit | 0.00 | 0.61 Cr | 0.00 | — | — |
| Non Current Prepaid Assets | 60.48 Cr | 59.33 Cr | 58.68 Cr | 57.89 Cr | — |
| Non Current Deferred Taxes Assets | 140.87 Cr | 146.31 Cr | 133.55 Cr | 113.15 Cr | — |
| Investmentin Financial Assets | 0.03 Cr | 0.03 Cr | 0.03 Cr | 0.01 Cr | — |
| Available For Sale Securities | 0.03 Cr | 0.03 Cr | 0.03 Cr | 0.01 Cr | — |
| Investment Properties | 0.78 Cr | 0.92 Cr | 1.06 Cr | 1.21 Cr | — |
| Goodwill And Other Intangible Assets | 13.33 Cr | 23.55 Cr | 34.09 Cr | 34.50 Cr | — |
| Other Intangible Assets | 13.33 Cr | 23.55 Cr | 34.09 Cr | 34.50 Cr | — |
| Net PPE | 283.86 Cr | 310.73 Cr | 315.12 Cr | 325.45 Cr | — |
| Accumulated Depreciation | -295.62 Cr | -283.13 Cr | -255.54 Cr | -222.66 Cr | — |
| Gross PPE | 579.48 Cr | 593.86 Cr | 570.66 Cr | 548.10 Cr | — |
| Construction In Progress | 14.32 Cr | 13.93 Cr | 20.31 Cr | 30.50 Cr | — |
| Other Properties | 269.54 Cr | 17.44 Cr | 13.80 Cr | 17.57 Cr | — |
| Machinery Furniture Equipment | 440.09 Cr | 448.86 Cr | 424.44 Cr | 393.70 Cr | — |
| Buildings And Improvements | 121.37 Cr | 127.37 Cr | 108.41 Cr | 104.08 Cr | — |
| Land And Improvements | 3.70 Cr | 3.70 Cr | 3.70 Cr | 2.25 Cr | — |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Assets | 3.41K Cr | 2.80K Cr | 2.49K Cr | 3.71K Cr | — |
| Other Current Assets | 0.23 Cr | 2.03 Cr | 3.19 Cr | 4.03 Cr | — |
| Restricted Cash | 26.16 Cr | 21.90 Cr | 20.10 Cr | 19.22 Cr | — |
| Prepaid Assets | 42.82 Cr | 42.70 Cr | 26.86 Cr | 42.00 Cr | — |
| Inventory | 481.74 Cr | 525.05 Cr | 459.97 Cr | 534.70 Cr | — |
| Finished Goods | 366.97 Cr | 412.96 Cr | 349.09 Cr | 422.83 Cr | — |
| Work In Process | 0.94 Cr | 0.81 Cr | 0.95 Cr | 0.88 Cr | — |
| Raw Materials | 113.83 Cr | 111.28 Cr | 109.93 Cr | 110.99 Cr | — |
| Other Receivables | 68.28 Cr | 127.86 Cr | 137.65 Cr | — | 25.72 Cr |
| Accounts Receivable | 292.55 Cr | 222.06 Cr | 192.38 Cr | 205.24 Cr | — |
| Allowance For Doubtful Accounts Receivable | -15.83 Cr | -13.45 Cr | -12.87 Cr | -20.23 Cr | — |
| Gross Accounts Receivable | 308.38 Cr | 235.51 Cr | 205.24 Cr | 225.47 Cr | — |
| Cash Cash Equivalents And Short Term Investments | 2.50K Cr | 1.86K Cr | 1.65K Cr | 2.90K Cr | — |
| Other Short Term Investments | 1.96K Cr | 1.79K Cr | 1.62K Cr | 2.62K Cr | — |
| Cash And Cash Equivalents | 538.85 Cr | 64.17 Cr | 34.94 Cr | 286.19 Cr | — |
| Cash Equivalents | 435.00 Cr | 0.00 | 0.04 Cr | 230.06 Cr | — |
| Cash Financial | 103.85 Cr | 64.17 Cr | 34.90 Cr | 56.13 Cr | — |
| Treasury Shares Number | — | 0.00 | — | — | — |
| Assets Held For Sale Current | — | — | 0.00 | 0.11 Cr | 180.12 Cr |
| Current Debt | — | — | — | 0.00 | 0.02 Cr |
| Long Term Debt | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on GlaxoSmithKline Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.